Fig. S5
Effects of Cpd3 exposure on pancreas development. A) Endocrine pancreas cells (black arrows) expressing islet1 are present by in situ hybridization in embryos treated with Cpd3 from 12 - 72 hpf. B) δ-cells expressing somatostatin (sst) (black arrows) are present by in situ hybridization in embryos treated with Cpd3 from 12 - 72 hpf. C) Quantification of exocrine pancreas size by area of trypsin expression at 72 hpf. 200 µM Cpd3 treatment elicits a robust reduction in pancreas size in heterozygote nr5a2+/oz3 embryos relative to control nr5a2+/oz3 siblings and control nr5a2+/+ embryos. (n > 5 per group; for control nr5a2+/+ vs. Cpd3 treated nr5a2+/+, p = 0.2498; for control nr5a2+/oz3 vs Cpd3 treated nr5a2+/oz3, p = 0.0027; for control nr5a2+/+ vs. Cpd3 treated nr5a2+/oz3, p = 0.0003; ordinary one-way ANOVA with Tukey’s multiple comparisons test).
Reprinted from Developmental Biology, 418(1), Nissim, S., Weeksb, O., Talbot, J.C., Hedgepeth, J.W., Wucherpfennig, J., Schatzman-Bone, S., Swinburne, I., Cortes, M., Alexa, K., Megason, S., North, T.E., Amacher, S.L., Goessling, W., Iterative use of nuclear receptor Nr5a2 regulates multiple stages of liver and pancreas development, 108-23, Copyright (2016) with permission from Elsevier. Full text @ Dev. Biol.